In this context, a dual-targeting strategy simultaneously inhibiting VEGFR-2 and K-RAS may offer synergistic therapeutic benefits, as it could suppress both angiogenesis and RAS-driven tumor cell proliferation. Here, KDR is linked to neoplasm.